Neoadjuvant chemotherapy in invasive bladder cancer

References

• Shipley WU, Kaufman DS, McDougal WS, Dahl DM, Michaelson MD, Zietman AL. Cancers of the genitourinary system. In: Cancer: Practice and Principles in Oncology. Seventh Edition. DeVita VT, Hellman S, Rosenberg SA (Eds). Lippincot & Williams, PA, USA (2004).
   Google Scholar
• Thrasher JB, Crawford ED. Current management of invasive and metastatic transitional cell cercinoma of the bladder. J. Urol. 14, 957–972 (1993).
   Google Scholar
• Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J. Urol. 174(1), 14–20 (2005).
   Google Scholar
• Frank I, Cheville JC, Blute ML et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathological features associated with outcome. Cancer 97, 2425–2429 (2003).
   PubMed Web of Science ®Google Scholar
• Sternberg C, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 13, 303–407 (1985).
   Google Scholar
• Sternberg C, Yakoda A, Scher HI et al. M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 139, 461–469 (1988).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PHM, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organisation for Research and Treatment of Cancer protocol no. 30924. J. Clin. Oncol. 19, 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 17, 3068–3077 (2000).
   Google Scholar
• Mead GM, Russell M, Clark P et al. A randomised trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. J. Cancer 8, 1067–1075 (1998).
   Google Scholar
• Sternberg CN, de Mulder PHM, Schornagel JH et al. Seven year update of an EORTC Phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. J. Clin. Oncol. 23, S384 (2005).
   Google Scholar
• Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet 3, 738–747 (2002).
   Google Scholar
• Rudat V, Pfreundner L, Hoppe F, Dietz A. Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer. Onkologie 27(4), 368–375 (2004).
   PubMedGoogle Scholar
• Green MC, Esteva FS, Hortubagyi GN. Neoadjuvant chemotherapy. Breast Dis. 21, 23–31 (2004).
   PubMedGoogle Scholar
• Naughton P, Walsh TN. Multimodality therapy for cancers of the esophagus and gastric cardia. Expert Rev. Anticancer Ther. 4, 141–150 (2004).
   PubMedGoogle Scholar
• Belani CP. Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin. Oncol. 32(2), S9–S15 (2005).
   Google Scholar
• Splinter TAW, Scher HI, Bukowski DR et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J. Urol. 14, 706–608 (1992).
   Google Scholar
• Scattoni V, Da Pozzo L, Nava L et al. Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. Eur. Urol. 28, 102–107 (1995).
   Google Scholar
• Schultz PK, Herr HW, Zhang Z-F et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J. Clin. Oncol. 12, 1394–1401 (1994).
   PubMedGoogle Scholar
• Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative MVAC. J. Clin. Oncol. 19, 4005–4013 (2001).
   PubMed Web of Science ®Google Scholar
• Herr HW, Whitmore WF, Morse MJ, Sogani PC, Russo P, Fair WR. Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery. J. Urol. 144, 1083–1088 (1990).
   PubMedGoogle Scholar
• Splinter TAW, Pavone-Macaluso M, Jaqmin D et al. A European Organization for Research and Treatment of cancer – Genitourinary Group Phase II study of chemotherapy in stage T3–4N0-XM0 transitional cell cancer of the bladder. Evaluation of clinical response. J. Urol. 148, 1793–1796 (1992).
   PubMedGoogle Scholar
• Sonpavde G, Petrylak DP. Perioperative chemotherapy for bladder cancer. Crit. Rev. Oncol. Hematol. (2005) (In Press).
   Google Scholar
• Scher HI, Yagoda A, Herr HW et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J. Urol. 13, 970–474 (1988).
   Google Scholar
• Scher H, Sternberg C, Fair W et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br. J. Urol. 6, 450–256 (1989).
   Google Scholar
• Sternberg CN, Arena MG, Calabresi F et al. Neo-adjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for infiltrating transitional cell carcinoma (TCC) of the bladder. Cancer 69, 1975–1982 (1993).
   Google Scholar
• Dreicer R, Kollmorgen TA, Smith RF, Williams RD. Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term follow-up. J. Urol. 150, 849–852 (1993).
   PubMedGoogle Scholar
• Bamias A, Deliveliotis C, Karayiannis A et al. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long-term results. Eur. Urol. 46, 344–350 (2003).
   Google Scholar
• Bamias A, Aravantinos G, Bafaloukos D et al. Docetaxel and Cisplatin versus M-VAC in advanced urothelial carcinoma: a multicenter, randomized, Phase III study conducted by the Hellenic Co-operative Oncology Group. J. Clin. Oncol. 2, 220–228 (2004).
   Google Scholar
• Sousa-Escandon A, Vazquez S, Quintero-Aldana G et al. Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a Phase II trial. Int. J. Urol. 9, 162–166 (2002).
   PubMed Web of Science ®Google Scholar
• Wallace DMA, Raghavan D, Kelly KA et al. Neo-adjuvant (Pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br. J. Urol. 67, 608–615 (1991).
   PubMedGoogle Scholar
• Pineiro-Martinez JA, Martin MG, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized Phase III study. J. Urol. 153, 964–973 (1995).
   PubMedGoogle Scholar
• Malstrom PU, Rintala E, Wahlqvist R et al. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial I. J. Urol. 155, 1903–1906 (1996).
   PubMedGoogle Scholar
• Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 14, 2901–2907 (1996).
   PubMed Web of Science ®Google Scholar
• Ghersi D, Stewart LA, Parmar MKB et al. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br. J. Urol. 75, 206–213 (1995).
   PubMedGoogle Scholar
• Sherif A, Rintala E, Mestad O et al. Neoadjuvant ciplatin-methotrexatre-chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand. J. Urol. Nephrol. 36, 419–425 (2002).
   PubMed Web of Science ®Google Scholar
• International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer. Lancet 354, 533–540 (1999).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• Sengelov L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle invasive bladder tumors. Acta. Oncol. 41, 447–456 (2002).
   PubMed Web of Science ®Google Scholar
• Hall RR. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc. Am. Soc. Clin. Oncol. 21, 178a (2002).
   Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361, 1927–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Abol-Enein H, El-MekreschM, El-Baz M, Ghoneim MA. Neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomized study. Br. J. Urol. 79(Suppl.), 174 (1997).
   Google Scholar
• Bassi P, Pappagallo GL, Sperandio P et al. Neoadjuvant MVAC chemotherapy of invasive bladder cancer: results of a multicenter Phase III trial. J. Urol. 161, 264A (1999).
   Google Scholar
• Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171, 561–565 (2004).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 48, 202–206 (2005).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Pansadoro V, Calabro F et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann. Oncol. 10, 1301–1305 (1999).
   PubMedGoogle Scholar
• Torres-Roca JF. Bladder preservation protocols in the treatment of muscle-invasive bladder cancer. Cancer Control 11, 358–363 (2004).
   PubMedGoogle Scholar
• Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N. Engl. J. Med. 329, 1377–1382 (1993).
   PubMed Web of Science ®Google Scholar
• Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group Phase II trial (8802). J. Clin. Oncol. 14, 119–126 (1996).
   Google Scholar
• Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89–03. J. Clin. Oncol. 16, 3576–3583 (1998).
   Google Scholar
• Danesi DT, Arcangeli G, Cruciani E et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy. Cancer 101(11), 2540–2548 (2005).
   Google Scholar
• Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N. Primary cisplatin, methotrexarte and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. J. Urol. 155, 1897–1902 (1996).
   PubMedGoogle Scholar
• Cooke PW, James ND, Ganesan R, Burton A, Young LS, Wallace DMA. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. Br. J. Urol. Int. 85, 829–835 (2000).
   Google Scholar
• Small EJ, Halabi S, Dalbagni G et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 97(Suppl. 8), 2090–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97(Suppl. 8), 2083–2090 (2003).
   PubMedGoogle Scholar